Advertisement

Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease

  • Ajeesh Koshy Cherian
  • Aaron Kucinski
  • Ryan Wu
  • Inge E. M. de Jong
  • Martin SarterEmail author
Original Investigation
  • 66 Downloads

Abstract

Rationale

Falls in patients with Parkinson’s disease (PD) are associated with cognitive, specifically attentional impairments and with losses in cholinergic projection systems. We previously established an animal model of the combined basal forebrain cholinergic—striatal dopaminergic losses of PD fallers (Dual Lesioned, DL, rats) and demonstrated that treating DL rats with an acetylcholinesterase inhibitor (AChEI), donepezil, together with a 5HT6 receptor antagonist, idalopirdine, reduced fall frequency and improved associated aspects of the performance of DL rats traversing rotating rods.

Objectives

Here, we employed a longer and more taxing rotating beam apparatus to determine the potential therapeutic efficacy of idalopirdine when combined with the pseudo-irreversible, and thus relatively long-acting, AChE- and butyrylcholinesterase- (BuChE) inhibitor rivastigmine.

Results

As before, vehicle-treated DL rats fell more frequently, committed more slips, and exhibited more movement stoppages than intact control rats. Repeated intermittent administration of rivastigmine and idalopirdine significantly improved the performance of DL rats. Rivastigmine alone also produced strong trends for reducing falls and slips. The combination treatment was more effective than rivastigmine alone in reducing stoppages and stoppage-associated falls. As before, idalopirdine treatment alone was ineffective.

Conclusions

These results extend the prediction that the combined treatment with idalopirdine and an AChEI improves complex movement control and reduces the propensity for falls in patients with movement disorders. Because of the importance of finding better treatments for gait and balance deficits in PD, the present results may further motivate a clinical exploration of the usefulness of this combination treatment.

Keywords

Rivastigmine Idalopirdine Acetylcholine Dopamine Basal ganglia Parkinson’s disease Falls 

Notes

Compliance with ethical standards

Conflict of interest

The research described in this manuscript was supported by a grant from H. Lundbeck A/S, Valby (Denmark) to M.S. I.d.J. is an employee of H. Lundbeck.

References

  1. Aizenberg D, Sigler M, Weizman A, Barak Y (2002) Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr 14:307–310CrossRefGoogle Scholar
  2. Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ (2009) Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord 15:110–115CrossRefGoogle Scholar
  3. Amat-Foraster M, Leiser SC, Herrik KF, Richard N, Agerskov C, Bundgaard C, Bastlund JF, de Jong IEM (2017) The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture. Neuropharmacology 113:45–59CrossRefGoogle Scholar
  4. Amboni M, Barone P, Hausdorff JM (2013) Cognitive contributions to gait and falls: evidence and implications. Mov Disord 28:1520–1533CrossRefGoogle Scholar
  5. Berry AS, Demeter E, Sabhapathy S, English BA, Blakely RD, Sarter M, Lustig C (2014) Disposed to distraction: genetic variation in the cholinergic system influences distractibility but not time-on-task effects. J Cogn Neurosci 26:1981–1991CrossRefGoogle Scholar
  6. Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221:564–573CrossRefGoogle Scholar
  7. Bohnen NI, Müller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:1670–1676CrossRefGoogle Scholar
  8. Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S, Albin RL, Frey KA (2012) Heterogeneity of cholinergic denervation in Parkinson’s disease without dementia. J Cereb Blood Flow Metab 32:1609–1617CrossRefGoogle Scholar
  9. Breese GR, Traylor TD (1971) Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 42:88–99CrossRefGoogle Scholar
  10. Chen TY, Peronto CL, Edwards JD (2012) Cognitive function as a prospective predictor of falls. J Gerontol B Psychol Sci Soc Sci 67:720–728CrossRefGoogle Scholar
  11. Chung KA, Lobb BM, Nutt JG, Horak FB (2010) Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75:1263–1269CrossRefGoogle Scholar
  12. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, HillsdaleGoogle Scholar
  13. Cole MH, Silburn PA, Wood JM, Kerr GK (2011) Falls in Parkinson’s disease: evidence for altered stepping strategies on compliant surfaces. Parkinsonism Relat Disord 17:610–616CrossRefGoogle Scholar
  14. Cowie D, Limousin P, Peters A, Hariz M, Day BL (2012) Doorway-provoked freezing of gait in Parkinson's disease. Mov Disord 27:492–499CrossRefGoogle Scholar
  15. Crick F (1984) Function of the thalamic reticular complex: the searchlight hypothesis. Proc Natl Acad Sci U S A 81:4586–4590CrossRefGoogle Scholar
  16. de Kam D, Nonnekes J, Oude Nijhuis LB, Geurts AC, Bloem BR, Weerdesteyn V (2014) Dopaminergic medication does not improve stepping responses following backward and forward balance perturbations in patients with Parkinson’s disease. J Neurol 261:2330–2337CrossRefGoogle Scholar
  17. Deane KH, Flaherty H, Daley DJ, Pascoe R, Penhale B, Clarke CE, Sackley C, Storey S (2014) Priority setting partnership to identify the top 10 research priorities for the management of Parkinson’s disease. BMJ Open 4:e006434CrossRefGoogle Scholar
  18. Ding J, Guzman JN, Tkatch T, Chen S, Goldberg JA, Ebert PJ, Levitt P, Wilson CJ, Hamm HE, Surmeier DJ (2006) RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 9:832–842CrossRefGoogle Scholar
  19. Dube L, Smith AD, Bolam JP (1988) Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J Comp Neurol 267:455–471CrossRefGoogle Scholar
  20. Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L (2017) Falls in Parkinson’s disease: a complex and evolving picture. Mov Disord 32:1524–1536CrossRefGoogle Scholar
  21. Ferris CF, Kulkarni P, Yee JR, Nedelman M, de Jong IEM (2017) The serotonin receptor 6 antagonist idalopirdine and acetylcholinesterase inhibitor donepezil have synergistic effects on brain activity—a functional MRI study in the awake rat. Front Pharmacol 8Google Scholar
  22. Gielow MR, Zaborszky L (2017) The input-output relationship of the cholinergic basal forebrain. Cell Rep 18:1817–1830CrossRefGoogle Scholar
  23. Gilat M, Shine JM, Walton CC, O'Callaghan C, Hall JM, Lewis SJG (2015) Brain activation underlying turning in Parkinson’s disease patients with and without freezing of gait: a virtual reality fMRI study. NPJ Parkinsons Dis 1:15020CrossRefGoogle Scholar
  24. Greenwald AG, Gonzalez R, Harris RJ, Guthrie D (1996) Effect sizes and p values: what should be reported and what should be replicated? Psychophysiology 33:175–183CrossRefGoogle Scholar
  25. Gritton HJ, Howe WM, Mallory CS, Hetrick VL, Berke JD, Sarter M (2016) Cortical cholinergic signaling controls the detection of cues. Proc Natl Acad Sci U S A 113:E1089–E1097CrossRefGoogle Scholar
  26. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211–225PubMedPubMedCentralGoogle Scholar
  27. Helboe L, Egebjerg J, de Jong IE (2015) Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study. Neuroscience 310:442–454CrossRefGoogle Scholar
  28. Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y (2016) Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:249–258CrossRefGoogle Scholar
  29. Heremans E, Nieuwboer A, Vercruysse S (2013) Freezing of gait in Parkinson’s disease: where are we now? Curr Neurol Neurosci Rep 13:350–359CrossRefGoogle Scholar
  30. Herrik KF, Mork A, Richard N, Bundgaard C, Bastlund JF, de Jong IE (2016) The 5-HT receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology 107:351–363CrossRefGoogle Scholar
  31. Hollman JH, Youdas JW, Lanzino DJ (2011) Gender differences in dual task gait performance in older adults. Am J Mens Health 5:11–17CrossRefGoogle Scholar
  32. Howe WM, Ji J, Parikh V, Williams S, Mocaër E, Trocmé-Thibierge C, Sarter M (2010) Enhancement of attentional performance by selective stimulation of alpha4beta2* nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 35:1391–1401CrossRefGoogle Scholar
  33. Howe WM, Gritton HJ, Lusk NA, Roberts EA, Hetrick VL, Berke JD, Sarter M (2017) Acetylcholine release in prefrontal cortex promotes gamma oscillations and theta-gamma coupling during cue detection. J Neurosci 37:3215–3230CrossRefGoogle Scholar
  34. Kim K, Muller M, Bohnen NI, Sarter M, Lustig C (2017a) The cortical cholinergic system contributes to the top-down control of distraction: evidence from patients with Parkinson's disease. Neuroimage.  https://doi.org/10.1016/j.neuroimage.2017.12.012
  35. Kim K, Muller M, Bohnen NI, Sarter M, Lustig C (2017b) Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: evidence from Parkinson's disease patients with defined cholinergic losses. Neuroimage 149:295–304CrossRefGoogle Scholar
  36. Kucinski A, Sarter M (2015) Modeling Parkinson’s disease falls associated with brainstem cholinergic systems decline. Behav Neurosci 129:96–104CrossRefGoogle Scholar
  37. Kucinski A, Paolone G, Bradshaw M, Albin R, Sarter M (2013) Modeling fall propensity in Parkinson’s disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci 33:16522–16539CrossRefGoogle Scholar
  38. Kucinski A, Albin RL, Lustig C, Sarter M (2015) Modeling falls in Parkinson’s disease: slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss. Behav Brain Res 282:155–164CrossRefGoogle Scholar
  39. Kucinski A, de Jong IE, Sarter M (2017) Reducing falls in Parkinson’s disease: interactions between donepezil and the 5-HT6 receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements. Eur J Neurosci 45:217–231CrossRefGoogle Scholar
  40. Lapper SR, Bolam JP (1992) Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51:533–545CrossRefGoogle Scholar
  41. Lewis SJG, Barker RA (2009) A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism Relat Disord 15:333–338CrossRefGoogle Scholar
  42. Naismith SL, Shine JM, Lewis SJG (2010) The specific contributions of set-shifting to freezing of gait in Parkinson’s disease. Mov Disord 25:1000–1004CrossRefGoogle Scholar
  43. Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet 52:225–241CrossRefGoogle Scholar
  44. Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A (2011) Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 10:734–744CrossRefGoogle Scholar
  45. O’Halloran AM, Penard N, Galli A, Fan CW, Robertson IH, Kenny RA (2011) Falls and falls efficacy: the role of sustained attention in older adults. BMC Geriatr 11:85CrossRefGoogle Scholar
  46. Parikh V, Man K, Decker MW, Sarter M (2008) Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 28:3769–3780CrossRefGoogle Scholar
  47. Parikh V, Ji J, Decker MW, Sarter M (2010) Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 30:3518–3530CrossRefGoogle Scholar
  48. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Violi F, Mannucci PM (2013) Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30:103–112CrossRefGoogle Scholar
  49. Pereira CL, Baptista F, Infante P (2013) Men older than 50 years are more likely to fall than women under similar conditions of health, body composition, and balance. Am J Phys Med Rehabil 92:1095–1103CrossRefGoogle Scholar
  50. Pickel VM, Beckley SC, Joh TH, Reis DJ (1981) Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res 225:373–385CrossRefGoogle Scholar
  51. Pitchers KK, Phillips KB, Jones JL, Robinson TE, Sarter M (2017) Diverse roads to relapse: a discriminative Cue signaling cocaine availability is more effective in renewing cocaine seeking in goal trackers than sign trackers and depends on basal forebrain cholinergic activity. J Neurosci 37:7198–7208CrossRefGoogle Scholar
  52. Ritchie CW, Ames D, Clayton T, Lai R (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12:358–369CrossRefGoogle Scholar
  53. Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B, Burn DJ (2012) Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain 135:2779–2788CrossRefGoogle Scholar
  54. Sarter M (2015) Behavioral-cognitive targets for cholinergic enhancement. Curr Opin Behav Sci 4:22–26CrossRefGoogle Scholar
  55. Sarter M, Fritschy JM (2008) Reporting statistical methods and statistical results in EJN. Eur J Neurosci 28:2363–2364CrossRefGoogle Scholar
  56. Sarter M, Parikh V, Howe WM (2009) nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol 78:658–667CrossRefGoogle Scholar
  57. Sarter M, Albin RL, Kucinski A, Lustig C (2014a) Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol 257:120–129CrossRefGoogle Scholar
  58. Sarter M, Lustig C, Howe WM, Gritton H, Berry AS (2014b) Deterministic functions of cortical acetylcholine. Eur J Neurosci 39:1912–1920CrossRefGoogle Scholar
  59. Sarter M, Howe WM, Gritton H (2015) Cortical cholinergic transients for cue detection and attentional mode shifts. In: Wilson G, Michael A (eds) Compendium of in vivo monitoring in real-time molecular neuroscience. World Scientific, Singapore, pp 27–44CrossRefGoogle Scholar
  60. Sarter M, Lustig C, Berry AS, Gritton H, Howe WM, Parikh V (2016a) What do phasic cholinergic signals do? Neurobiol Learn Mem 130:135–141CrossRefGoogle Scholar
  61. Sarter M, Lustig C, Blakely RD, Koshy Cherian A (2016b) Cholinergic genetics of visual attention: human and mouse choline transporter capacity variants influence distractibility. J Physiol Paris 110:10–18CrossRefGoogle Scholar
  62. Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G (2002) Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 109:1067–1080CrossRefGoogle Scholar
  63. Shine JM, Moustafa AA, Matar E, Frank MJ, Lewis SJ (2013) The role of frontostriatal impairment in freezing of gait in Parkinson’s disease. Front Syst Neurosci 7:61CrossRefGoogle Scholar
  64. St Peters M, Demeter E, Lustig C, Bruno JP, Sarter M (2011) Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci 31:9760–9771CrossRefGoogle Scholar
  65. Steriade M, Parent A, Paré D, Smith Y (1987) Cholinergic and non-cholinergic neurons of cat basal forebrain project to reticular and mediodorsal thalamic nuclei. Brain Res 408:372–376CrossRefGoogle Scholar
  66. Vercruysse S, Devos H, Munks L, Spildooren J, Vandenbossche J, Vandenberghe W, Nieuwboer A, Heremans E (2012) Explaining freezing of gait in Parkinson’s disease: motor and cognitive determinants. Mov Disord 27:1644–1651CrossRefGoogle Scholar
  67. Wall NR, De La Parra M, Callaway EM, Kreitzer AC (2013) Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 79:347–360CrossRefGoogle Scholar
  68. Weaver TB, Robinovitch SN, Laing AC, Yang Y (2016) Falls and Parkinsons disease: evidence from video recordings of actual fall events. J Am Geriatr Soc 64:96–101CrossRefGoogle Scholar
  69. Wilkinson D, Windfeld K, Colding-Jorgensen E (2014) Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 13:1092–1099CrossRefGoogle Scholar
  70. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, Mason RS, Chen JS, Cumming RG, Sambrook PN (2011) Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 59:875–880CrossRefGoogle Scholar
  71. Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinsons disease. Mov Disord 26:2496–2503CrossRefGoogle Scholar
  72. Zikopoulos B, Barbas H (2007) Circuits for multisensory integration and attentional modulation through the prefrontal cortex and the thalamic reticular nucleus in primates. Rev Neurosci 18:417–438CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PsychologyUniversity of MichiganAnn ArborUSA
  2. 2.Division of NeurodegenerationH. Lundbeck A/SValbyDenmark

Personalised recommendations